Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis.
Ejskjaer N, Vestergaard ET, Hellström PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L, Kosutic G. Ejskjaer N, et al. Among authors: kosutic g. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1179-87. doi: 10.1111/j.1365-2036.2009.03986.x. Epub 2009 Feb 27. Aliment Pharmacol Ther. 2009. PMID: 19298585 Clinical Trial.
Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study.
Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen LC, Sarosiek I, Søfteland E, Nowak T, Pezzullo JC, Shaughnessy L, Kosutic G, McCallum R. Ejskjaer N, et al. Among authors: kosutic g. Neurogastroenterol Motil. 2010 Oct;22(10):1069-e281. doi: 10.1111/j.1365-2982.2010.01519.x. Epub 2010 Jun 28. Neurogastroenterol Motil. 2010. PMID: 20524987 Clinical Trial.
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.
Wo JM, Ejskjaer N, Hellström PM, Malik RA, Pezzullo JC, Shaughnessy L, Charlton P, Kosutic G, McCallum RW. Wo JM, et al. Among authors: kosutic g. Aliment Pharmacol Ther. 2011 Mar;33(6):679-88. doi: 10.1111/j.1365-2036.2010.04567.x. Epub 2011 Jan 7. Aliment Pharmacol Ther. 2011. PMID: 21214610 Clinical Trial.
Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study.
Wargin W, Thomas H, Clohs L, St-Louis C, Ejskjaer N, Gutierrez M, Shaughnessy L, Kosutic G. Wargin W, et al. Among authors: kosutic g. Clin Drug Investig. 2009;29(6):409-18. doi: 10.2165/00044011-200929060-00004. Clin Drug Investig. 2009. PMID: 19432500 Clinical Trial.
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Sandborn WJ, et al. Among authors: kosutic g. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1. Aliment Pharmacol Ther. 2015. PMID: 26031921 Clinical Trial.
20 results